Vedana: Taking a two-pathway shot at migraine

Vedana aims to build on the success of CGRP drugs in migraine by targeting PACAP, a second attack-triggering neuropeptide. Launched Wednesday with $46 million in series A funding, the Seattle-based newco is developing long-acting antibodies against PACAP, including a bispecific with CGRP.

“If we look at the migraine prevention therapy over the last four decades, every decade we have had one drug,” co-founder and CEO Anurag Agarwal told BioCentury. “First it was topiramate, then botox, then CGRP. Now it feels like the decade of PACAP coming.”...